Activate Now
ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Do You Have These Fibromyalgia Symptoms of Systemic Dysfunction?

Fibromyalgia Is Finally Recognized as an Official Diagnosis!

Meet Devin Starlanyl: Fibromyalgia and Chronic Myofascial Pain Expert

The Fibromyalgia – Negativity Connection

Which Infection Causes CFS & Fibromyalgia?

Simplifying Nutritional Support in CFS & Fibromyalgia

Need Help with Pain Management? There's an App for That

6 Reasons Why Trigger Point Injections Aren't Helping Your Fibromyalgia

Exercise: Friend or Foe in Fibromyalgia?

How Multiple Chronic Illnesses Shaped One Woman Into a Patient Advocate

Print Page
Email Article

9.5-Year Follow-Up on Effects of Rituximab in RA Patients

  [ 6 votes ]   [ Discuss This Article ] • November 9, 2012

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
– Source: Annals of Rheumatic Diseases, Nov 7, 2012

By Ronald F van Vollenhoven, et al.

[Note: The full text of this article is available free here. Rheumatoid arthritis is associated with elevated risks of serious infections, lymphomas and fatal cardiovascular events. The drug rituximab is used in combination with methotrexate to control autoimmune damage to RA patients' joints by reducing levels of a specific immune B-cell that attacks them. The therapy initially elevates risk of infection and malignancy somewhat. This long-term tracking study reflected a concern about the possibility that repeated courses of rituximab might further increase these risks. The findings will be of interest to researchers conducting experimental trials of rituximab as a potential treatment for ME/CFS as well.]

Objectives: Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA).


Pooled observed case analysis of data from patients with moderate-to-severe, active RA treated with rituximab in a global clinical trial program.

As of September 2010, 3,194 patients had received up to 17 rituximab courses over 9.5 years (11,962 patient-years). Of these, 627 had more than 5 years' follow-up (4,418 patient-years).

A pooled placebo population (n=818) (placebo + methotrexate (MTX)) was also analyzed.

Serious adverse event and infection rates generally remained stable over time and multiple courses.

• The overall serious infection event (SIE) rate was 3.94 per 100 patient-years (3.26 per 100 patient-years in patients observed for more than 5 years) and was comparable with placebo+MTX (3.79 per 100 patient-years).

• Serious opportunistic infections were rare.

• Overall, 22.4% (n=717) of rituximab-treated patients developed low immunoglobulin (Ig)M and 3.5% (n=112) low IgG levels for 4 months or more after 1 or more courses.

• Serious infection event rates were similar before and during/after development of low Ig levels; however, in patients with low IgG, rates were higher than in patients who never developed low IgG.

• Rates of myocardial infarction and stroke were consistent with rates in the general RA population.

• No increased risk of malignancy over time was observed.


This analysis demonstrates that rituximab remains generally well tolerated over time and multiple courses, with a safety profile consistent with published data and clinical trial experience.

Overall, the findings indicate that there was no evidence of an increased safety risk or increased reporting rates of any types of adverse events with prolonged exposure to rituximab during the 9.5 years of observation.

Source: Annals of the Rheumatic Diseases, Nov 7, 2012. PMID:23136242, by van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, Tyson N, Collinson N, Lehane PB. Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden. [Email:]

Please Discuss This Article:   Post a Comment 

[ Be the first to comment on this article ]

Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Subscribe Now!
Receive up-to-date ME/CFS, Fibromyalgia & Lyme Disease treatment and research news
 Privacy Guaranteed  |  View Archives

Vitamins and Supplements for Fibromyalgia Support

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Guaifenesin FA™ Guaifenesin FA™
Natural Expectorant Relieves Chest Congestion
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth

Natural Remedies

Safely Burn Away Body Fat Safely Burn Away Body Fat
Itching to Find Dry Skin Relief? Itching to Find Dry Skin Relief?
Complete and Natural Menopause Relief Complete and Natural Menopause Relief
Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry

What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Causes
Fibromyalgia Treatments
Fibromyalgia Diet
Fibromyalgia Medications
M.E. & CFS
What is M.E./CFS?
M.E./CFS Diagnosis
M.E./CFS Symptoms
M.E./CFS Causes
M.E./CFS Treatments
M.E./CFS Diet
M.E./CFS Medications
What is Lyme Disease?
Lyme Disease Diagnosis
Lyme Disease Symptoms
Lyme Disease Causes
Lyme Disease Treatments
Lyme Disease Diet
Lyme Disease Medications
M.E. & CFS
Lyme Disease
General Health
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing